[
    [
        {
            "time": "2021-11-01",
            "original_text": "华熙生物(688363.SH)：向133名激励对象授予96万股限制性股票",
            "features": {
                "keywords": [
                    "华熙生物",
                    "激励对象",
                    "限制性股票",
                    "授予"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "华熙生物(688363.SH)：向133名激励对象授予96万股限制性股票",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "2021-11-01",
            "original_text": "财信证券：给予华熙生物买入评级，目标价位271.9元",
            "features": {
                "keywords": [
                    "财信证券",
                    "华熙生物",
                    "买入评级",
                    "目标价"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "财信证券：给予华熙生物买入评级，目标价位271.9元",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-11-01",
            "original_text": "财信证券维持华熙生物推荐评级：营收维持高增，利润短期承压，坚持长期看好",
            "features": {
                "keywords": [
                    "财信证券",
                    "华熙生物",
                    "营收高增",
                    "利润承压",
                    "长期看好"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "mixed"
            },
            "scores": {
                "News_content": "财信证券维持华熙生物推荐评级：营收维持高增，利润短期承压，坚持长期看好",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-11-01",
            "original_text": "华熙生物(688363.SH)向激励对象授予96万股限制性股票 授予价为116元/股",
            "features": {
                "keywords": [
                    "华熙生物",
                    "激励对象",
                    "限制性股票",
                    "授予价"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "华熙生物(688363.SH)向激励对象授予96万股限制性股票 授予价为116元/股",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2021-11-01",
            "original_text": "国货群星闪耀时，讲述者成为共创人",
            "features": {
                "keywords": [
                    "国货",
                    "群星闪耀",
                    "共创人"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "消费品"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "国货群星闪耀时，讲述者成为共创人",
                "Correlation": 4,
                "Sentiment": 6,
                "Importance": 3,
                "Impact": 3,
                "Duration": 4,
                "Entity_Density": 2,
                "Market_Scope": 5,
                "Time_Proximity": 4,
                "Headline_Structure": 8,
                "Source_Recency": 4
            }
        },
        {
            "time": "2021-11-01",
            "original_text": "A股早报2021年11月1日星期一",
            "features": {
                "keywords": [
                    "A股早报",
                    "2021年11月1日"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "A股早报2021年11月1日星期一",
                "Correlation": 3,
                "Sentiment": 5,
                "Importance": 3,
                "Impact": 3,
                "Duration": 3,
                "Entity_Density": 1,
                "Market_Scope": 6,
                "Time_Proximity": 2,
                "Headline_Structure": 5,
                "Source_Recency": 2
            }
        },
        {
            "time": "2021-11-01",
            "original_text": "私募大佬放大招！看邓晓峰、冯柳、裘国根等最新持仓",
            "features": {
                "keywords": [
                    "私募大佬",
                    "邓晓峰",
                    "冯柳",
                    "裘国根",
                    "最新持仓"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "私募大佬放大招！看邓晓峰、冯柳、裘国根等最新持仓",
                "Correlation": 3,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 1,
                "Market_Scope": 7,
                "Time_Proximity": 4,
                "Headline_Structure": 9,
                "Source_Recency": 4
            }
        },
        {
            "time": "2021-11-01",
            "original_text": "Q3行情结束，医药板块进入估值切换长周【东吴医药朱国广团队】",
            "features": {
                "keywords": [
                    "Q3行情",
                    "医药板块",
                    "估值切换",
                    "东吴医药"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Q3行情结束，医药板块进入估值切换长周【东吴医药朱国广团队】",
                "Correlation": 6,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 8,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        }
    ]
]